Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide vs insulin glargine on cardiac function in type 2 diabetes with heart failure (NYHA II)
2008-005325-10Phase 4Active
- Sponsor
- VU University Medical Center
- Start
- Oct 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of exenatide in type 2 diabetes mellitus (T2DM) and heart failure (HF) (2 arms), sponsored by VU University Medical Center. Primary endpoint: Global cardiac function (ejection fraction). Started Oct 2008; status: active.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on 2008-005325-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005325-10.